Arecor Therapeutics PLC Arecor granted key European patent (0611A)
18 Gennaio 2024 - 8:00AM
UK Regulatory
TIDMAREC
RNS Number : 0611A
Arecor Therapeutics PLC
18 January 2024
Arecor Therapeutics plc
("Arecor" or the "Group")
ARECOR GRANTED KEY EUROPEAN PATENT EXTENDING PROTECTION FOR
INSULIN PRODUCTS, AT278 AND AT247
Cambridge, UK, 18 January 2024: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, is pleased to announce that the European
Patent Office has granted a patent ( EP3618840) protecting novel
formulations of the Group's proprietary insulin products, AT278 and
AT247. The European patent adds to a comprehensive global
intellectual property (IP) portfolio protecting the Group's novel
insulin products and follows additional patents of similar scope
recently granted in Australia, India and Mexico.
Jan Jezek, Chief Scientific Officer at Arecor, commented : "We
continue to build a strong intellectual property portfolio in key
markets for our ultra-fast acting insulin products, AT278 and
AT247, which provide the Group significant growth potential in a
multi-billion dollar market driven by the need for tighter glucose
control and the rise of innovative delivery devices and digital
technologies. AT278, our 'disrupter insulin' with its high
concentration and ultra-rapid profile has the potential to be the
gold standard insulin for the growing population of people with
high daily insulin needs and an essential component to enable patch
pump miniaturisation and extended wear-time. Further data to
support its profile are expected in H1 2024 from the Group's
clinical trial in a type 2 diabetes population."
Arecor has built a comprehensive IP portfolio protecting the
Group's Arestat(TM) technology platform and proprietary pipeline
products. The portfolio, which comprises 36 patent families and
>90 granted patents in Europe, the US and in other key
territories, includes several patent families providing robust IP
protection of the Group's proprietary insulin products until at
least 2037.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
ICR Consilium
Chris Gardner, David Daley, Lindsey Tel: +44 (0) 20 3709 5700
Neville Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary formulation technology
platform, Arestat(TM) , we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat (TM) platform is supported by an extensive patent portfolio
.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSFWFWWELSEFF
(END) Dow Jones Newswires
January 18, 2024 02:00 ET (07:00 GMT)
Grafico Azioni Arecor Therapeutics (LSE:AREC)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Arecor Therapeutics (LSE:AREC)
Storico
Da Set 2023 a Set 2024